Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole for Cancer-Related Cognitive Impairment
NCT06580002Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer-related cognitive impairment (CRCI) comparing Riluzole with Placebo (2 arms). Primary endpoint: Brain-Derived Neurotrophic Factor at 8 weeks. Started Dec 2024; status: recruiting.
02
Drugs
riluzole
03
Conditions
cancer-related cognitive impairment (CRCI)
Beyond the preview
Go deeper on NCT06580002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580002.